Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea ; volume:150 ; number:5 ; day:20 ; month:5 ; year:2024 ; pages:1-13 ; date:5.2024
Journal of cancer research and clinical oncology ; 150, Heft 5 (20.5.2024), 1-13, 5.2024

Urheber
Lee, Hyun Kyung
Jang, Ha Young
Kim, In-Wha
Oh, Jung Mi
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00432-024-05800-8
URN
urn:nbn:de:101:1-2408162114565.017546348990
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:01 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Lee, Hyun Kyung
  • Jang, Ha Young
  • Kim, In-Wha
  • Oh, Jung Mi
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

Verbundene Objekte